Logo image of AFMD

AFFIMED NV (AFMD) Stock Price, Quote, News and Overview

NASDAQ:AFMD - Nasdaq - NL0015001ZQ0 - Common Stock - Currency: USD

0.9347  +0.04 (+5.02%)

AFMD Quote, Performance and Key Statistics

AFFIMED NV

NASDAQ:AFMD (4/25/2025, 8:00:00 PM)

0.9347

+0.04 (+5.02%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High8.95
52 Week Low0.52
Market Cap14.24M
Shares15.23M
Float14.31M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)05-21 2025-05-21
IPO09-12 2014-09-12


AFMD short term performance overview.The bars show the price performance of AFMD in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 -20 40 -40 -60

AFMD long term performance overview.The bars show the price performance of AFMD in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of AFMD is 0.9347 USD. In the past month the price increased by 16.11%. In the past year, price decreased by -81.42%.

AFFIMED NV / AFMD Daily stock chart

AFMD Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.39 329.14B
AMGN AMGEN INC 14.17 150.99B
GILD GILEAD SCIENCES INC 13.33 128.61B
VRTX VERTEX PHARMACEUTICALS INC 1702.9 126.96B
REGN REGENERON PHARMACEUTICALS 13.2 65.88B
ARGX ARGENX SE - ADR 330.52 37.54B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 32.72B
ONC BEIGENE LTD-ADR N/A 26.39B
BNTX BIONTECH SE-ADR N/A 24.52B
NTRA NATERA INC N/A 20.79B
BIIB BIOGEN INC 7.22 17.39B
SMMT SUMMIT THERAPEUTICS INC N/A 17.30B

About AFMD

Company Profile

AFMD logo image Affimed NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of cancer immunotherapies. The company is headquartered in Heidelberg, Baden-Wuerttemberg and currently employs 76 full-time employees. The company went IPO on 2014-09-12. The firm's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28 and AMF32. The firm is enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. Its preclinical product candidates include AMF26 for treating multiple myeloma, as well as AMF28 and AMF32, for treating of multiple tumor targets. In addition, the Company collaborates with Genentech to develop and commercialize certain product candidates for treating multiple cancers.

Company Info

AFFIMED NV

Im Neuenheimer Feld 582

Heidelberg BADEN-WUERTTEMBERG 69120 DE

CEO: Adi Hoess

Employees: 76

Company Website: https://www.affimed.com/

Investor Relations: https://www.affimed.com/investors

Phone: 49621560030

AFFIMED NV / AFMD FAQ

What is the stock price of AFFIMED NV today?

The current stock price of AFMD is 0.9347 USD. The price increased by 5.02% in the last trading session.


What is the ticker symbol for AFFIMED NV stock?

The exchange symbol of AFFIMED NV is AFMD and it is listed on the Nasdaq exchange.


On which exchange is AFMD stock listed?

AFMD stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for AFFIMED NV stock?

11 analysts have analysed AFMD and the average price target is 12.24 USD. This implies a price increase of 1209.51% is expected in the next year compared to the current price of 0.9347. Check the AFFIMED NV stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is AFFIMED NV worth?

AFFIMED NV (AFMD) has a market capitalization of 14.24M USD. This makes AFMD a Nano Cap stock.


How many employees does AFFIMED NV have?

AFFIMED NV (AFMD) currently has 76 employees.


What are the support and resistance levels for AFFIMED NV (AFMD) stock?

AFFIMED NV (AFMD) has a resistance level at 1.45. Check the full technical report for a detailed analysis of AFMD support and resistance levels.


Is AFFIMED NV (AFMD) expected to grow?

The Revenue of AFFIMED NV (AFMD) is expected to decline by -81.84% in the next year. Check the estimates tab for more information on the AFMD EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy AFFIMED NV (AFMD) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does AFFIMED NV (AFMD) stock pay dividends?

AFMD does not pay a dividend.


When does AFFIMED NV (AFMD) report earnings?

AFFIMED NV (AFMD) will report earnings on 2025-05-21.


What is the Price/Earnings (PE) ratio of AFFIMED NV (AFMD)?

AFFIMED NV (AFMD) does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.2).


What is the Short Interest ratio of AFFIMED NV (AFMD) stock?

The outstanding short interest for AFFIMED NV (AFMD) is 4.13% of its float. Check the ownership tab for more information on the AFMD short interest.


AFMD Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to AFMD. When comparing the yearly performance of all stocks, AFMD is a bad performer in the overall market: 92.43% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

AFMD Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to AFMD. AFMD has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

AFMD Financial Highlights

Over the last trailing twelve months AFMD reported a non-GAAP Earnings per Share(EPS) of -5.2. The EPS increased by 42.15% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -175.1%
ROE -406.92%
Debt/Equity 0.35
Chartmill High Growth Momentum
EPS Q2Q%41.25%
Sales Q2Q%-92.1%
EPS 1Y (TTM)42.15%
Revenue 1Y (TTM)-95.39%

AFMD Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 84% to AFMD. The Buy consensus is the average rating of analysts ratings from 11 analysts.

For the next year, analysts expect an EPS growth of 40.97% and a revenue growth -81.84% for AFMD


Ownership
Inst Owners22.64%
Ins Owners6.01%
Short Float %4.13%
Short Ratio5.94
Analysts
Analysts83.64
Price Target12.24 (1209.51%)
EPS Next Y40.97%
Revenue Next Year-81.84%